Catabasis Pharmaceuticals, Inc. (CATB) Set to Announce Earnings on Wednesday
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) will be releasing its earnings data after the market closes on Wednesday, August 9th. Analysts expect Catabasis Pharmaceuticals to post earnings of ($0.40) per share for the quarter.
Catabasis Pharmaceuticals, Inc. (NASDAQ CATB) opened at 1.2663 on Monday. Catabasis Pharmaceuticals, Inc. has a 52-week low of $1.08 and a 52-week high of $7.89. The company has a 50-day moving average price of $1.30 and a 200 day moving average price of $1.59. The company’s market capitalization is $28.45 million.
CATB has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Catabasis Pharmaceuticals in a research note on Wednesday, April 26th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $9.00 target price (down from $11.00) on shares of Catabasis Pharmaceuticals in a research note on Monday, May 15th. Finally, Zacks Investment Research downgraded shares of Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 19th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $5.30.
WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/07/catabasis-pharmaceuticals-inc-catb-set-to-announce-earnings-on-wednesday.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Stock Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.